Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. provided extensive research and development updates, highlighting new clinical data across epilepsy, autoimmune and neuroscience programs. Its Kv7.2/7.3 activator opakalim in idiopathic generalized epilepsy tripled median time to a second generalized tonic-clonic seizure to 141 days versus 47 days on placebo in a small randomized trial and showed no somnolence, dizziness or fatigue. In focal epilepsy, an open-label extension analysis found 54% of six‑month completers on opakalim 75 mg once daily achieved at least a 50% seizure reduction, with low central nervous system adverse event rates compared with other antiseizure medicines. Biohaven also reported Phase 1b data for its extracellular degraders: BHV‑1300 reduced Graves’ disease TSHR‑IgG1 autoantibodies by over 80% with associated normalization of thyroid hormones, while BHV‑1400 lowered pathogenic Gd‑IgA1 by more than 60% within 48 hours and 70% within one month in IgA nephropathy, alongside early improvements in kidney function markers. Early safety across these programs was described as favorable, and Biohaven plans pivotal Phase 3 trials in Graves’ disease and IgA nephropathy by mid‑2026 while advancing additional CNS candidates such as PKM2 activator BHV‑8100 and tinnitus spray BHV‑1955.
Janus Henderson Group plc reports beneficial ownership of 11.7% of Biohaven Ltd. As disclosed, Janus Henderson's Asset Managers hold 17,534,612 common shares of Biohaven Ltd as beneficial owners as of 03/31/2026, with shared voting and dispositive power over those shares. The filing states the Asset Managers exercise voting discretion for Managed Portfolios but disclaim rights to dividends or sale proceeds, and that no single Managed Portfolio owns more than 5% of the class.
Biohaven Ltd. entered into Amendment No. 2 to its Equity Distribution Agreement with J.P. Morgan Securities LLC, establishing an “at-the-market” equity offering program. From May 4, 2026, the company may sell up to an aggregate offering price of $350.0 million in common shares through J.P. Morgan as manager.
Shares may be sold on the New York Stock Exchange or via other negotiated transactions at prevailing market prices, with actual sales determined over time by the company’s capital needs and market conditions. The program is issued under an effective shelf registration statement and related base prospectus and prospectus supplement filed on May 4, 2026.
Biohaven Ltd. is offering common shares having an aggregate offering price of up to $350,000,000 through an amendment dated May 4, 2026 to its equity distribution agreement with J.P. Morgan Securities LLC. The shares will be sold as at-the-market offerings from time to time. The company reported 150,506,490 common shares outstanding as of March 31, 2026. Sales may occur in ordinary brokers’ transactions, to or through market makers, on the NYSE or other permitted venues, and the sales agent may act as agent or principal. The sales agent may receive up to 3.00% of gross proceeds as compensation.
Biohaven Ltd. filed a Form S-3 shelf registration to permit the offering from time to time of common shares, preferred shares, depositary shares, debt securities, warrants, rights, purchase contracts and units, including resale by certain selling shareholders. The shelf contemplates primary issuances and resales by selling stockholders and states proceeds to the company will be used for general corporate purposes. The prospectus incorporates Biohaven’s Form 10-K for the year ended December 31, 2025, its Form 10-Q for the quarter ended March 31, 2026, and Current Reports on Form 8-K (including filings on January 7, 2026 and May 4, 2026), and notes that supplements will specify offering terms, plan of distribution and any selling stockholder details.
Biohaven Ltd. reported a first-quarter 2026 net loss of $130.5M, an improvement from $221.7M a year earlier, driven by sharply lower research and development and general and administrative spending. Total operating expenses fell to $130.4M from $221.6M, reflecting portfolio and cost-optimization efforts.
Cash and cash equivalents were $273.1M and marketable securities were $74.7M as of March 31, 2026, supporting management’s view that existing liquidity should fund operations for at least one year after the statements’ issuance. Net cash used in operating activities was $149.9M for the quarter.
To bolster its balance sheet, Biohaven issued 17,164,940 common shares under its at-the-market equity program, generating net proceeds of $178.9M and increasing outstanding shares to 150,506,490. Notes payable tied to a revenue-sharing Note Purchase Agreement had a fair value of $241.9M, highlighting a significant non-traditional financing obligation linked to future sales and regulatory milestones. The company continues to focus on three key late-stage programs in Kv7 ion channel modulation, MoDE/TRAP extracellular protein degraders, and myostatin-activin pathway targeting for neuromuscular and metabolic diseases.
Biohaven Ltd. reported first quarter 2026 results showing a smaller loss and stronger balance sheet while advancing multiple late-stage drug programs. Net loss narrowed to $130.5 million, or $0.88 per share, compared with $221.7 million, or $2.17 per share, a year earlier.
R&D expenses fell to $103.8 million from $187.6 million, mainly from program reprioritization and lower preclinical and share-based compensation costs. Cash, cash equivalents, marketable securities and restricted cash totaled $351.8 million as of March 31, 2026, supporting a broad pipeline across epilepsy, obesity, immunology, oncology and Parkinson’s disease.
The company expects pivotal epilepsy data for opakalim and Phase 2 obesity data for taldefgrobep alfa in the second half of 2026, and plans to start pivotal trials for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy by mid-2026. Non-GAAP adjusted net loss improved to $102.2 million, or $0.69 per share, as Biohaven continues disciplined cost management while progressing its clinical programs.
Biohaven Ltd. reported the results of its 2026 annual meeting of shareholders. Shareholders elected Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin as directors for terms expiring at the 2029 annual meeting, each receiving over 76 million votes in favor and more than 14 million votes against, with additional abstentions and 32,137,064 broker non-votes.
Shareholders also approved the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, with 123,723,636 votes for, 214,123 against, and 1,410,634 abstentions. In addition, they approved the non-binding advisory vote on compensation for the company’s named executive officers, with 87,521,620 votes for, 4,202,883 against, 1,486,826 abstentions, and 32,137,064 broker non-votes.
Biohaven Ltd. director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026. Each option gives the right to buy one common share at an exercise price of $9.61 and expires on April 28, 2036.
According to the vesting terms, all 68,693 options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided Mehta continues to serve with the company through that vesting date.
Biohaven Ltd. director Gregory Bailey reported receiving a grant of stock options as part of his compensation. The award covers 68,693 stock options, each allowing him to buy one common share at an exercise price of $9.61 per share.
The options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company until that vesting date. After this grant, he holds 68,693 options directly, and this filing does not show any open-market buying or selling of shares.